Publication Month: Jan 2021 | Report Code: TIPRE00008992 | No. of Pages: 155 | Category: Pharmaceuticals | Status: Published
The COVID-19 pandemic has disrupted supply chain of over-the-counter (OTC) and prescription drugs, and this is likely to limit the market growth in the next few quarters. Moreover, the emphasis of health care providers and medical industries on COVID-19 has led to the lowered focus on the diagnosis and treatment for gastroparesis, which is limiting the market growth to a certain extent.
Gastric emptying is associated with the coordination among the motor activity of proximal stomach, distal stomach, and duodenum. These internal organs are controlled by the feedback mechanism from neural signals generated through the interaction between nutrients and small intestine. Aging leads to diminished homeostatic regulations of physiologic functions, along with the slowing of gastric emptying. Moreover, it influences motor and sensory functions. In addition, geriatric population is highly vulnerable to gastroparesis due to factors such as the poor oral medication absorption, inadequate appetite regulation, and postprandial glycemia. According to the 2019 revision of World Population Prospects, 1 in 6 people would be aged more than 65 by 2050, with an increase from 1 in 11 in 2019. Furthermore, according to the same study, one in four people in Europe and North America is projected to be aged over 65 by 2050. Also, the number of people with age more than 80 would reach 426 million by 2050 from 143 million in 2019. Thus, the continuous increase in aging population, coupled with the rise in issues associated with gastric emptying among these populations, drives the gastroparesis market growth.
On the basis of type, the gastroparesis market is segmented into idiopathic, diabetic, post-surgical, and others. The idiopathic segment held the largest share of the market in 2019, while the diabetic segment is estimated to register the highest CAGR during the forecast period.
The gastroparesis market, based on drug class type, is segmented into prokinetic agents, antiemetic agents, and botulinum toxin injections. The prokinetic agents segment held the largest market share in 2019 and is estimated to register the highest CAGR during 2020–2027.
On the basis of distribution channel, the gastroparesis market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest share of the market in 2019, and the market for the same is estimated to grow at the highest CAGR from 2020 to 2027.
|Market Size Value in||US$ 4,338.61 Million in 2019|
|Market Size Value by||US$ 6,025.11 million by 2027|
|Growth rate||CAGR of 4.3% from 2020-2027|
|No. of Pages||155|
|No. of Tables||84|
|No. of Charts & Figures||72|
|Historical data available||Yes|
|Segments covered||Gastroparesis Type , Drug Class Type , and Distribution Channel|
|Regional scope||North America, Europe, Asia Pacific, Middle East & Africa, South & Central America|
|Country scope||US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Free Sample Copy Available|
The gastroparesis market players have been adopting the strategy of product innovations to cater to dynamic customer demands, which also allows them to maintain their brand name in the global market.
The List of Companies - Gastroparesis Market